EN
EN
FR
ES
PT
AR
RU
DE
IT
NL
TH
KO
VI
ID
Home
Kexing Biopharm
About Us
Kexing Brand
Brand Connotation
Corporate Culture
Honors
History
Global Business
Global Commercial Cooperation Strategy
Commercialization platform
Commercialization capability
Commercial Cooperation Graph
R&D and Innovation
Global R&D Center
R&D field
Animal Vaccine
Synthetic Biology
SANCTINUS
Our Medicines
Infliximab for Injection
Bevacizumab Injection
Adalimumab Solution for Injection
Paclitaxel for Injection(Albumin-Bound)
Human Erythropoietin Injection
Human Granulocyte Colony-stimulating Factor Injection
Combined Clostridium and Bifidobacterium,Live
Human Interferon α1b for Injection
Kehuang Capsule
Entecavir Tablets
α-ketoglutarate(AKG)
5-aminnolevulinic acid (5-ALA)
Recombinant Collagen Repair Mask
Recombinant Collagen Anti-Wrinkle Single Use Essence
Quality Control
Quality system
Compliant production
Pharmacovigilance
ESG
Global health
Support Community
Environmental protection
News
News and information
Video Center
Contact
Contact Us
Join Us
NEWS AND INFORMATION
Home
/
News
/
News and information
/
Kexing Biopharm...
Kexing Biopharm's Product List (FDA and EMA Approved)
Article source：Kexing Biopharm
Jun 17,2025
View： 1706
LABEL:
< Harnessing the Power of Recombinant Collagen Repair Mask for Youthful Skin
Kexing Biopharm's Product Introduction >
BACK TO LIST
Related News
Dec 31,2024
The Future of Medicine: Exploring Recombinant Protein Drug Suppliers
READ MORE >>
Oct 13,2023
Celebrating Medical Advancements: The Marvel of Paclitaxel Injection
READ MORE >>
Apr 08,2024
Completion of PIC/S Participating Authorities' Audits of Kexing Biopharm's licensed Product Infliximab for Injection
READ MORE >>
Jul 13,2023
Kexing Biopharm won the sole agency for the first-time generic drug of infliximab, demonstrating strong superiority in ...
READ MORE >>
Jul 13,2023
China's first infliximab biosimilar drug ready for export, Kexing Biopharm initiated drug registration in 17 countries
READ MORE >>
Jul 13,2023
Kexing Biopharm Attend the 5th Greater Bay Area Biopharmaceutical Innovators Summit
READ MORE >>
Home
Kexing Biopharm
About Us
Kexing Brand
Brand Connotation
Corporate Culture
Honors
History
Global Business
Global Commercial Cooperation Strategy
Commercialization platform
Commercialization capability
Commercial Cooperation Graph
R&D and Innovation
Global R&D Center
R&D field
Animal Vaccine
Synthetic Biology
SANCTINUS
Our Medicines
Infliximab for Injection
Bevacizumab Injection
Adalimumab Solution for Injection
Paclitaxel for Injection(Albumin-Bound)
Human Erythropoietin Injection
Human Granulocyte Colony-stimulating Factor Injection
Combined Clostridium and Bifidobacterium,Live
Human Interferon α1b for Injection
Kehuang Capsule
Entecavir Tablets
α-ketoglutarate(AKG)
5-aminnolevulinic acid (5-ALA)
Recombinant Collagen Repair Mask
Recombinant Collagen Anti-Wrinkle Single Use Essence
Quality Control
Quality system
Compliant production
Pharmacovigilance
ESG
Global health
Support Community
Environmental protection
News
News and information
Video Center
Contact
Contact Us
Join Us
Article source：Kexing Biopharm
Jun 17,2025
View：
1706 
BACK TO LIST
Dec 31,2024
